ArticleMolecular therapy. Methods & clinical development2020
Dosing and Re-Administration of Lentiviral Vector for
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.Gene therapy · 2026Article
- SEM1 Downregulates HSPA8 to Suppress TLR4/MyD88/NF-κB Signaling and Alleviate Myocardial I/R Injury.International journal of molecular sciences · 2026Article
- Computational design of membrane fusion proteins.bioRxiv : the preprint server for biology · 2026Article
- Biology and therapeutic potential of extracellular vesicle targeting and uptake.Nature reviews. Molecular cell biology · 2026Review
- Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics.Molecular biotechnology · 2025Article
- The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Evaluation of Purification Methods for Minimizing Transgene Expression Background During Viral Manufacturing.Human gene therapy · 2025Article
- Therapeutic antibody delivery: vector tools to boost efficacy and affordability.Frontiers in immunology · 2025Review
- Gender difference in pre-clinical liver-directed gene therapy with lentiviral vectors.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Gene therapy of Dent disease type 1 in newborn ClC-5 null mice for sustained transgene expression and gene therapy effects.Gene therapy · 2024Article
- Reprogramming Extracellular Vesicles for Protein Therapeutics Delivery.Pharmaceutics · 2021Article
- Gene delivery using AAV8Molecular therapy. Methods & clinical development · 2021Article
- Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Article
- Gene Therapy for Primary Immunodeficiency.HemaSphere · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Adenosine deaminase (ADA)-deficient mice and healthy rhesus monkeys were studied to determine the impact of age at treatment, vector dosage, dosing schedule, repeat administration, biodistribution, and immunogenicity after systemic delivery of lentiviral vectors (LVs). In
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.